The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

Psychedelic antidepressants approved Esketamine-based antidepressants have been approved in countries such as France and the United States, where dextromethorphan is also used. Australia has gone ...

Why was the FDA approval of esketamine so controversial among many researchers? Researchers Mark Horowitz and Joanna Moncrieff, both psychiatrists, noted (in the British Journal of Psychiatry in ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson ...

Two cutting edge treatments for though-to-treat major depression are remarkably successful: TMS Therapy and Spravato (Esketamine) treatment. TMS is safe, medication free and covered by insurance.

Esketamine, the ketamine-derived nasal spray sold under the brand name Spravato (esketamine), is indicated for patients with treatment-resistant depression. In October 2023, the FDA warned about ...

Spravato (esketamine) has been touted as a potential blockbuster for Janssen, which faces increasing biosimilar competition from its top-selling rheumatoid arthritis drug Remicade. Estimates from ...

The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free survival. The approval was based on results from CodeBreaK 300, a phase 3 ...